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S
mall interfering RNAs (siRNAs) are
2123 nucleotide double strand nu-
cleic acid molecules that assemble
into speciﬁc complexes in mammalian cells
to mediate cleavage of complementary
mRNA sequences and thus regulate gene
expression.1 As a result, their use as a tool
fortargetvalidation,geneticstudies,andfor
therapy of diseases that are rooted in aber-
rant gene expression, such as cancer,2,3 has
become increasingly popular.49 However,
unlike small molecule drugs that are often
hydrophobic and easily cross the cell mem-
brane, siRNAs are negatively charged and
cannot freely trafﬁc to the cytoplasm of the
target cells. Thus, delivery of intact, func-
tional siRNAs into the cytoplasm of target
cells in vivo is a major impediment to realiz-
ing the potential of siRNA-based protein
modulation in disease.
To date, several formulations that de-
liver siRNAs into cells in vitro and in vivo
have been reported. siRNA backbone or
end-groups modiﬁcations that impart siRNA
serum stability and improve cell mem-
brane penetration have been used success-
fully to knockdown genes in vivo.10,11
Protamine-antibody fusions have also been
used to successfully transfect HIV infected T
cells.12 Lipid-based and lipid-derived nano-
particles that carry siRNAs either in their
core or via covalent attachment have been
reported to have signiﬁcant efﬁcacy in vivo
and in vitro.1315 However, these formula-
tions do not contain imaging agents that
can be traced in vivo to assess the location
of the carrier and siRNAs. To address this is-
sue, many research groups have used quan-
tum dots,16 magnetic17 and gold
nanoparticles18,19 as well as carbon nano-
tubes20 and enabled successful siRNA/ anti-
sense delivery in vitro,16,19,20 with a few re-
ports on in vivo imaging of these
nanoparticles.17 However, in these reports
(where inorganic nanoparticles are used),
covalent coupling of siRNAs is used to for-
mulate the nanoparticles which makes
rapid testing of various siRNA formulations
a cumbersome and iterative process. Thus,
to screen for maximum efﬁcacy, it is desir-
able to have a simple formulation that af-
fords use of different siRNAs in a variety of
dosages. Finally, most nanoparticle-based
siRNA delivery reports use a model gene to
demonstrate knockdown in non-native tis-
sues of animals, which may not be equiva-
lent to a native disease model. Overall,
while the above reports highlight signiﬁ-
cant advances in siRNA delivery, there is a
need for a versatile siRNA delivery vehicle
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ABSTRACT SmallinterferingRNAs(siRNAs)mediatecleavageofspeciﬁc,complementarymRNAsequences
andthusregulategeneexpression.Notsurprisingly,theirusefortreatmentofdiseasesthatarerootedinaberrant
geneexpression,suchascancer,hasbecomeaparadigmthathasgainedwideinterest.Here,wereportthe
developmentofdendrimer-conjugatedmagnetoﬂuorescentnanowormsthatwecall“dendriworms”asamodular
platformforsiRNAdeliveryinvivo.Thisplatformmaximizesendosomalescapetorobustlyproduceproteintarget
knockdowninvivo,andistoleratedwellinmousebrain.WedemonstratethatsiRNA-carryingdendriwormscan
bereadilyinternalizedbycellsandenableendosomalescapeacrossawiderangeofloadingdoses,whereas
dendrimersornanowormsaloneareinefﬁcient.Further,weshowthatdendriwormscarryingsiRNAagainstthe
epidermalgrowthfactorreceptor(EGFR)reduceproteinlevelsofEGFRinhumanglioblastomacellsby7080%,
2.5-foldmoreefﬁcientlythancommercialcationiclipids.Dendriwormswerewell-toleratedafter7-daysof
convection-enhanceddeliverytothemousebrainandinanEGFR-driventransgenicmodelofglioblastoma,anti-
EGFRdendriwormsledtospeciﬁcandsigniﬁcantsuppressionofEGFRexpression.Collectively,thesedataestablish
dendriwormsasamultimodalplatformthatenablesﬂuorescenttrackingofsiRNAdeliveryinvivo,cellularentry,
endosomalescape,andknockdownoftargetproteins.
KEYWORDS: dendrimer · siRNA · nanoparticle · EGFR · glioblastoma
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be used in vivo in a native disease model.
In this work we report synthesis, systematic in vitro
evaluation, and in vivo application of polyvalent,
dendrimer-bearing, magnetic nanoparticles (dendri-
worm) as a carrier for siRNA delivery in a transgenic mu-
rinemodelofglioblastoma.Theconstructovercomesis-
sues highlighted above. First, dendriworms contain
magnetic core and are labeled ﬂuorescently to enable
imaging in a variety of formats. Second, we establish
that dendriworms promote cytosolic release of the en-
docytosed cargo more efﬁciently than their compo-
nents, resulting in efﬁcient delivery of siRNA to the cell
cytoplasm over a wide range of loading doses. Finally,
noncovalent attachment of siRNA affords dendriworms
the ability to retain ﬂexibility in siRNA loading without
reformulation and enabled a smooth transition to in
vivo applications where dendriworms were well toler-
ated after 7 days of convection-assisted delivery in the
CNS and resulted in knockdown of EGFRvIII in a trans-
genic model of glioblastoma. In the future, this multi-
modal platform may be further enhanced to include af-
ﬁnity ligands for targeting to particular cells of interest.
RESULTS AND DISCUSSION
Polyamidoamine (PAMAM) dendrimers are cationic
polymers that have been extensively evaluated as can-
didates for gene delivery.21 Dendrimers are branched,
multivalent macromolecules that were ﬁrst reported
nearly two decades ago.22,23 Dendrimers can be synthe-
sized to have neutral, cationic,22 or anionic24 groups in
a cascade polymer form, enabling facile regulation of a
number of functional groups, size, and charge. Mul-
tiple surface groups on dendrimers can be linked with
polymers,25 amino acids,26 tissue targeting moieties,27,28
drugs,2931 nucleic acid molecules,32 or imaging
agents33 to modulate properties of the dendrimer-
based drug or imaging agent carriers.34,35
SynthesisandCharacterizationofDendriworms.Whileden-
drimers have been used for delivery of genes21,36 and anti-
sense oligonucleotides,37,38 delivery of siRNA with dendrim-
ers has been challenging37 and only poor efﬁciencies have
been reported.38,39 A recent report demonstrates use of gen-
eration 7 PAMAM dendrimers for siRNA delivery,40 but most
efforts using lower generation dendrimers for siRNA delivery
have been unsuccessful37,38 and it has been shown that
lower generation dendrimers are poor at forming uniform,
stable particles with siRNAs.41 In a recent report, generation
6 polylysine dendrimers were also found to be inefﬁcient for
delivery of siRNAs.39 Since dendrimers buffer the endo-
somes via their tertiary and secondary amines, we hypoth-
esized that polyvalent conjugation of lower generation den-
drimers onto an elongated magnetic nanoparticle host
could generate a construct that would induce high proton
sponge effect and enable efﬁcient endosomal escape of siR-
NAs. Use of lower generation dendrimers may also diminish
the likelihood of immune system activation and inﬂamma-
tory response associated with the use of higher generation
dendrimers.42 Also, to encourage further in vivo use, we
chose a magnetic nanoparticle scaffold that could be conju-
gated to ﬂuorophores or imaged via magnetic resonance
imaging.
The synthesis of dendrimer-conjugated magnetic
nanoworms (dendriworms) is shown in Figure 1A. First,
Figure 1. Synthesis and characterization of dendriworms: (A) synthesis scheme; (B) siRNA binding characteristics. Dendriworm and siR-
NAs were allowed to bind in varying ratios and run on a gel. Strong binding between the dendriworm and siRNA at roughly 1:10 ratio
(measured using iron core concentration) prevents siRNAs from entering the gel.
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reduced in 0.5 M dithiothreitol (DTT), and excess DTT
was removed using a G25 chromatography column.
Next, amine-modiﬁed, cross-linked iron oxide nano-
worms, labeled with near-infrared ﬂuorochromes (Vi-
voTag 680, Visen Medical, Inc.), were prepared as de-
tailed in the Experimental Section. Finally, reduced
dendrons and nanoworms were conjugated using the
heterobifuctional linker N-succinimidyl 3-(2-
pyridyldithio)-propionate, which links amine groups on
the nanoparticle with the central thiols on reduced den-
drons (Figure 1A; see Experimental Section for details).
The resulting dendriworms were separated from free
dendrons by ﬁltering several times using either 100,000
molecular weight cutoff ﬁlter (Amicon Ultra, Millipore
Corp.), magnetic separation column (MACS, Miltenyi
Biotech), or G50 chromatography columns. Dendri-
worms were stored at 4 °C protected from light and
were stable for at least 6 months. Net charge on dendri-
worms was found to be between 1624 mV (zeta-
potential measurement in 1 PBS) and the average hy-
drodynamic diameter was found to be between 80
and 110 nm (dynamic light scattering measurements
in 1 PBS, Zetasizer Nano, Malvern, Inc.). In the trans-
mission electron micrograph, the particles were found
to retain a worm-shape, where multiple 58 nm iron
oxide cores were lined in a series (data not shown).43
The number of dendrons per dendriworm was found to
be 4550 using ﬂuorescamine and ninhydrin tests (as-
suming there are approximately 7 iron cores per dendri-
worm). Further, using UVvis absorbance measure-
ments, the number of VivoTag on each dendriworm
was found to be between 1 and 5. A key feature of the
dendriworms is that dendrons are conjugated via a re-
ducible linker (SPDP) to the nanoparticle surface. This
may allow removal of dendrons from the nanoparticle
surface in the reducing intracellular environment, re-
sulting in improved siRNA delivery and diffusion inside
cells. Variations of magnetic-core particles were also
generated using other polymers [polyethyleneimine,
myristic acid] and generations 36 of PAMAM den-
drimers. However, these particles were found to be in-
effective for gene silencing either due to a lack of colloi-
dal stability or due to poor siRNA delivery efﬁciency
and were therefore not pursued further (data not
shown).
Next, the binding afﬁnity of siRNA and dendriworms
was tested by incubating varying amounts of dendri-
worms (10400 nM iron core) with 1 M of siRNA for
10 min at room temperature and measuring the
amount of siRNA left unbound. The mixture was run
on a 15% TBE gel (BioRad Laboratories) at 80 mV for 1 h
and siRNAs in the gel were stained with SYBR Gold (In-
vitrogen Inc., Carlsbad, CA) Figure 1B. Because dendri-
worms are large and positively charged, they do not
electrophorese into the gel toward the cathode and are
washed from the top of the gel during the 1 h run. Fur-
ther, dendriworms bound to siRNAs remain positively
charged (zeta-potential measurements), causing siRNA
binding to dendriworms to retard siRNA movement
into the gel. At 50 nM dendriworm (iron core concn.),
some loss in siRNA band (21 bp) intensity was observed
and at 100 nM dendriworm (iron core concn.), nearly
complete siRNA retardation was seen. Thus, roughly
910 siRNA molecules are bound to each iron core in
dendriworm. This implies roughly 50 siRNA molecules
loaded on each dendriworm (there are roughly 7 iron
cores per dendriworm). To maintain consistency,
amounts of dendriworm and nanoworm are expressed
in iron core concentration in the rest of the manuscript.
The stability of the siRNA-dendriworm nanoparticle
was assessed in fetal bovine serum (FBS) and artiﬁcial
cerebrospinal ﬂuid (ACSF) by gel electrophoresis and
dynamic light scattering. To visualize the residual
bound siRNA, 1% SDS was used to release the siRNA
prior to electrophoresis. In ACSF the nanoparticle and
the bound siRNA remained stable for up to 6 h (Sup-
porting Information, Figure S1); however, the siRNA
showed lower stability in serum (data not shown).
Dendriworms Enable Efﬁcient Release of Cargo into the Cell
Cytosol. Cationic polymers adhere to the negatively
charged moieties on the cell membrane and may be
taken up via ﬂuid phase endocytosis or via receptor me-
diated endocytosis.44 As a result, a cargo that is only ac-
tive in the cell cytoplasm and is delivered using cat-
ionic polymers or cationic nanoparticles needs to
escape the endosomes. To test our hypothesis that con-
jugating multiple cationic dendrimers on a nanoworm
scaffold would enhance the proton sponge effect, lead-
ing to better cytosolic release of cargos, we evaluated
the efﬁciency of dendriworm endosomal escape com-
pared to free dendrimers. To assess endosomal escape,
we codelivered excess of a membrane impermeable
dye (Calcein at 0.25 mM) along with the siRNA delivery
agent (dendrimer, unmodiﬁed nanoworms and dendri-
worms) coupled with siRNAs and counted the fraction
of cells with endosomal escape as indicated by diffuse
cytoplasmic distribution of the dye.45,46
The results of these endosomal escape experiments
are shown in Figure 2. Aminated nanoworms (200 nM
iron core), dendrimer (30 M), or dendriworm (200 nM
iron core) were incubated with 100 nM siRNA in serum-
free cell culture medium containing excess of Calcein
for 10 min at room temperature and transferred over
the cells. The cells were kept at 37 °C and 5% CO2 envi-
ronment for 1 h and imaged using an inverted micro-
scope. In the presence of Calcein alone, punctate cyto-
plasmic distribution of dye was consistent with the
endosomal uptake. Some degree of endosomal release
as judged by diffuse cytoplasmic distribution was seen
with aminated nanoworms. Signiﬁcantly more endoso-
mal escape was seen with both dendrimers and dendri-
worms, although the extent of endosomal escape was
much greater with dendriworms. Endosomal escape is
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worms into the endosomes which depends on primary
amines on the surface of dendrimers that are positively
charged in serum (near pH 7). Thus, addition of more
negatively charged siRNAs that neutralize the positively
charged primary amines may reduce the number of
dendrimers or dendriworms that are able to load into
the endosomes, affecting the number of buffering (ter-
tiary) amines per endosome available for inducing en-
dosomal escape. Indeed, when higher concentrations
of siRNA were mixed with dendrimers or dendriworms,
dendrimers failed to induce signiﬁcant endosomal es-
cape while dendriworms remained effective even when
incubated with 1 M siRNA (Figure 2B,C). Thus conjuga-
tion of several dendrons (reduced half of a dendrimer)
onto aminated nanoworms allows for more effective
endosomal escape.
Next, we examined the cytotoxicity of dendriworms
at concentrations used in our studies. Two types of tox-
icity assays relying on either mitochondrial reductase
enzyme activity (MTT assay, based on reduction of (3-
(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) or on intracellular esterase activity (Calcein AM
assay) were used. No signiﬁcant in vitro toxicity across
various dendriworm and siRNA concentrations used in
this report was observed (Supporting Information, Fig-
ure S2).
DendriwormsDeliversiRNAintoCellsandInduceGene
Silencing. We have shown that dendriworms are able to
deliver cargo into cells efﬁciently at concentrations that
have negligible toxic effects on cells in vitro. Next, we
examined whether dendriworms could be used to de-
liver siRNAs into human primary glioblastoma cells
(GBM-6)47,48 that express mutant EGFRvIII, and induce
gene silencing. EGFRvIII gene silencing (knockdown) in
glioblastoma cells was assessed by measuring EGFR
protein expression levels and the amount of mRNA
transcripts compared with levels of a housekeeping
gene (GAPDH) (Figure 3). Both protein and mRNA lev-
els were suppressed signiﬁcantly and were compa-
rable to the commercial transfection agent Lipo-
fectamine 2000 when 100 nM siRNA was delivered.
Greater relative (dendriworm vs Lipofectamine 2000)
gene silencing was observed at protein level than at
mRNA level. One potential cause for this could be the
dependence of mRNA read-out method (qRT-PCR) on
several rounds of ampliﬁcation, which may attenuate
the differences if the initial number of mRNAs is differ-
ent but high in two samples. Gene silencing was found
to be strongly dependent on siRNA and dendriworm
dose (Figure 3). The knockdown was also sequence de-
pendent as lamin siRNA did not lower the expression
levels of EGFR (Figure 3).49 Further, EGFR siRNA deliv-
ered using aminated nanoworms or dendrimers did not
produce signiﬁcant EGFR knockdown (Supporting Infor-
mation, Figures S4, S5). In addition to GMB-6 cells, den-
driworms also produce signiﬁcant gene knockdown in
HeLa cells (Supporting Information, Figure S3) al-
though, consistent with the literature on the variability
of polymeric formulation dependent siRNA
delivery,5052 the extent of knockdown in HeLa cells is
lower. Taken together these results imply that dendri-
worms are a highly effective siRNA delivery vehicle for
GBM-6 glioblastoma cells and represent a ﬂexible for-
Figure 2. Dendriworms enable efﬁcient escape of endosomal cargos. Various formulations containing varying amounts of
siRNA were incubated with HeLa cells in the presence of excess Calcein for 1 h, and phase contrast (PC) and ﬂuoresence (FL)
images were taken at 20 magniﬁcation (A) or 100 magniﬁcation (B). Percent of cells with endosome escape as judged
by diffuse cytoplasmic spread of Calcein was plotted to assess efﬁciency of siRNA delivery (C).
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timization of siRNA delivery to other cell types.
SystemicDeliveryofDendriworms.Weevaluatedtheutility
of dendriworm-based siRNA delivery in mice. When dendri-
worms (20 g of iron in 100 Lo f1 PBS) were injected in
the bloodstream via tail vein injections, preferential accumu-
lation in the lungs, as expected from the cationic nature of
the particles,53 was seen (Supporting Information, Figure S6).
Brieﬂy, Swiss Webster mice were injected in the tail vein
with ﬂuorescently labeled dendriworms and the amount of
ﬂuorescence remaining in the blood at various time points
was measured. This was done by drawing blood at different
time points, removing cells and debris via centrifugation at
800rpmfor5min,andmeasuringtheﬂuorescencefromthe
supernatant using an Odyssey infrared imaging system (Li-
Cor Biosciences, Inc.). In this experiment, dendriworms
cleared the blood within in 5 min (Supporting Information,
Figure S9).
To further probe where the particles were accumulat-
ing, 100 Lo f1  PBS containing 20 g of dendriworms
or 20 g of ﬂuorescently labeled CLIO-NH2 or 1 PBS
alone was injected in the tail vein of mice and the mice
were sacriﬁced after approximately 10 min of injections.
After further 10 min, the organs were removed, washed
with saline, and imaged with Odyssey infrared imaging
system (Li-Cor Biosciences, Inc.). Since dendriworms were
labeled with infrared emitting dye VivoTag680, ﬂuores-
cence could be used to infer the degree of uptake of par-
ticles in various organs. Images were color coded to re-
ﬂect the intensity of uptake (Supporting Information,
Figure S6, left). After observing signiﬁcant accumulation
in the lungs (also conﬁrmed using histology; data not
shown), we sought to test if the accumulation was lung-
speciﬁc. To test this, one pair of Swiss Webster mice was
injected with PBS and the other pair of mice was injected
with dendriworms, in the left heart ventricle. The results
from this experiment are shown in the right side of Fig-
ure S6. The results show that dendriworms still accumu-
late in the lungs and the reticuloendothelial ﬁltration
organs.
Therefore, we sought to use dendriworms in vivo
via means that do not depend on systemic circulation
of the particles to reach the target organ or tissue (e.g.,
intraperitoneal cavity or intravenous injections).
Figure 3. Delivery of EGFR siRNA into glioblastoma cells with dendriworms. (A) EGFR protein levels were assessed using
Western blot with GAPDH as a housekeeping gene. Lamin siRNA was used as a control for testing sequence speciﬁcity and
Lipfectamine 2000 was used as a positive control. EGFR/GAPDH expression ratio was plotted from at least three independent
experiments. (B) EGFR to GAPDH mRNA transcript level ratio was calculated using qRT-PCR. Concentration of dendriworm ex-
pressed in iron core concentration. The asterisk (*) represents a p-value of 0.05.
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DendriwormsReducesEGFRExpressioninGBMTumors.Giventhe
efﬁcacy of RNA interference in GBM cells in vitro,w e
studied the effects of siRNA delivery by dendriworms
to the brain parenchyma. First, we determined the bio-
distribution within CNS tissues of healthy CD-1 outbred
mice, by formulating 0.5 mg/mL ﬂuorescently labeled
dendriworms with 0.115 mg/mL siRNAs intracranial in-
fusion for a period of 3 days and 7 days using an os-
motic pump delivering particles at a rate of 0.5 L/h.
Particles were observed in tissue sections from both the
posterior and the anterior locations with respect to the
injection site for both the 3 days delivery (Figure4)B ,C ,
and D and 7 days delivery (Supporting Information, Fig-
ure S7). We observed that the nanoparticles were able
to penetrate throughout the brain parenchyma in a
distance-dependent fashion as reﬂected in greater ﬂuo-
rescence intensity levels in the tissue sections closer to
the site of injection and detectable nanoparticles at the
far border (Figure 4B). Dendriworms were found to be
present at the perinuclear region in cells in vivo (Figure
4C,D and Supporting Information, Figure S7) consistent
with the particles entering the cells. Histopathological
evaluation of the injected animals revealed no discern-
ible pathology at the concentration used (Supporting
Information, Figure S7B), conﬁrming the lack of carrier-
induced toxicity from dendriworms. These data suggest
applicability of dendriworms for siRNA delivery into
CNS tissues via sustained, convection-enhanced deliv-
ery. On the basis of these results, a concentration of
0.5 mg/mL of dendriworm was chosen for further in
vivo studies.
To test dendriworms’ delivery efﬁcacy in vivo,w e
used a genetically engineered mouse model of glioblas-
toma, in which expression of oncogenic EGFR variant
III leads to de novo GBM tumor formation.54 At 20 days
post tumor initiation, VivoTag 680 dye-labeled dendri-
worms carrying an EGFR siRNA or a GFP siRNA or ami-
nated nanoworms carrying EGFR siRNA were delivered
intratumorally in brain tumor bearing animals by
convection-enhanced delivery using an osmotic pump
for a period of 7 days at 0.5 mg/mL of dendriworm and
0.115 mg/mL of siRNA (11 g total siRNA). Post infu-
sion, animals were sacriﬁced and immunoﬂuorescence
was performed on the tumor sections to analyze EGFR
knock down. The images and the results from quantiﬁ-
cation of EGFR expression are shown in Figure 5 (also
see Supporting Information, Figure S8). In the animal
treated with dendriworms carrying EGFR siRNA, strong
and signiﬁcant suppression of EGFR expression was
seen (Figure 5A,D) compared with the animal treated
with dendriworms carrying GFP siRNA (Figure 5B,D) or
the aminated nanoworms mixed with EGFR siRNA
(Figure 5C,D). On the other hand, similar amount of
nanoparticles were taken up in the brain across the
three treatments (Figure 5D). In fact, even with slightly
higher nanoparticle uptake in the control samples, the
level of EGFR expression was much higher than in the
Figure 4. Biodistribution of nanoparticles in the brain. (A) Schematic representation of a sagittal mouse brain showing posi-
tion of the tissue sections analyzed after 3 days of nanoparticle delivery with respect to the site of injection (a: anterior, p:
posterior)(B)Quantiﬁcationofnanoparticledistributionwithinvariousbrainsectionsbasedonthenanoparticleﬂuorescence
intensity (normalized to the maximum average mean intensity). (C) Images showing distribution of nanoparticles in tissue
section near the site of injection (at 1 mm) and in a tissue section far from the site of injection (at 4 mm) at a lower (top im-
age, scale bar is 100 m) and higher (bottom image, scale bar is 500 m) magniﬁcation. DAPI is shown in blue. The nano-
particles are color coded red and indicated by arrow heads in the higher magniﬁcation images.
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mulation. Furthermore, distinct mismatch in location
of nanoparticles and EGFR expression was seen in the
sections from dendriworm  EGFR siRNA treated
samples while signiﬁcant overlap and even colocaliza-
tion of nanoparticles with EGFR was seen in the other
control samples. Using a relevant de novo GBM model
system whereby tumor cells grow and migrate through
the microenvironment similar to what is observed in
human patients is necessary for ascertaining the pen-
etrating power of dendriworms. Our data demonstrate
that dendriworms are not only able to diffuse into brain
tumors but can also deliver siRNA into the tumor cells,
resultinginsigniﬁcantgenesilencinginvivo.Inthiscon-
text, these results reveal that the use of dendriworms
for siRNA delivery to GBM may have a clear clinical im-
pact on this disease.
CONCLUSION
In this work, we demonstrate a systematic design-
based approach to achieve siRNA delivery, both in vitro
and in vivo, using dendriworms. We also demonstrate
the correlation between the extent of endosomal es-
cape and the efﬁciency of gene silencing. The marked
enhancement in endosomal escape efﬁciency of den-
driworms compared to dendrimers or nanoworms sug-
gests that enrichment of polymers along the nano-
worm backbone promotes improved proton sponge
effect and endosomal escape, resulting in better siRNA
silencing. This paradigm can be applied to other gene
delivery polymers to design polyvalent, nanoparticle-
based siRNA delivery agents that are effective across
various cell lines and amenable to multimodal in vivo
detection and tracking.
Using dendriworms, we also demonstrate signiﬁ-
cant suppression of EGFR expression levels in glioblas-
toma cells and in vivo in a transgenic mouse model of
glioblastoma.54 This ﬁnding has clinical signiﬁcance be-
cause glioblastoma multiforme is an especially aggres-
sive form of cancer often with elevated expression lev-
els of EGFR.5558 Further, inhibition of EGFR activity has
been demonstrated to be clinically beneﬁcial in a sub-
set of patients59 implying that elimination of EGFR sig-
naling through gene expression knockdown may result
in positive clinical outcomes.
The combination of delivery, imaging, and target-
ing capabilities within dendriworms offers a versa-
tile and powerful agent to combat malignant glioma.
Availability of several primary amine groups on den-
driworms makes them an attractive platform for con-
jugating other entities that can modulate their tu-
mor uptake, biodistribution, and tissue homing
properties. The magnetic core in dendriworms
should also allow in vivo imaging of dendriworms
via MR. Finally, while several methods for the deliv-
ery of nanotechnology-based therapeutics for treat-
ment of malignant gliomas have been developed,60
in most cases, these entities offer a single modality
of detection or delivery and have proven to be toxic
at functional concentrations, which is in contrast
Figure 5. In vivo knockdown of EGFR expression in transgenic mice. (A) EGFR siRNA delivered with dendriworms, (B) GFP
siRNA delivered with dendriworms, (C) EGFR siRNA delivered with nanoworm-NH2, and (D) quantitative analysis of EGFR ex-
pression per cell or nanoparticle (NP) uptake relative to number of cells (DAPI) using data from 6 separate sections from a
mouse for each treatment (all images included in the Supporting Information). See Experimental Section for quantiﬁcation
details. Scale bar is 100 m.
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driworms. Thus, in conclusion, dendriworms are po-
tent siRNA delivery nanoparticles for in vivo applica-
tions and offer an unprecedented versatility.
EXPERIMENTAL SECTION
Chemicals and Reagents. Unless noted otherwise, all chemical
were purchased from Sigma-Aldrich, Inc. All nonproprietary siR-
NAs were obtained from Dharmacon, Inc.
Synthesis of Dendriworms. Cross-linked iron oxide nanoparticles
were synthesized using published methods.61,62 Brieﬂy, 4.5 g of
Dextran (Mr 1500025000) and 0.63 g of FeCl3·6H 2O were dis-
solved in 10 mL of cold, sterile water in a round-bottom ﬂask
purged with nitrogen and kept in an ice bath. Freshly prepared
solution of 0.25 g FeCl2·4H 2O in cold 5 mL sterile water was in-
jected into the ﬂask while the solution was stirred at 800 rpm.
Next, 1 mL of cold ammonia was added into the ﬂask dropwise.
After 10 min the reaction was allowed to proceed at 80 °C for 1 h.
The resulting reaction product was diluted 1:4 in sterile water
and ﬁltered (Amicon Ultra-4 MWCO: 100 000). Finally, the par-
ticles were ﬁltered using 0.2 m, 32 mm syringe ﬁlters (Pall Cor-
poration, East Hills, NY) to remove large particles and aggregates.
A 1.5 mL alilquot of particles was cross-linked by adding a mix-
ture of 2.5 mL of 5 M NaOH and 1 mL of epicholohydrin and al-
lowingthereactiontoproceedwithstirringatroomtemperature
for 24 h. Resulting particles were dialyzed using 50 000 MWCO
membrane and aminated overnight by adding 10% ammonia.
Cross-linked, aminated iron oxide particles were activated
with 500-fold excess of SPDP (N-succinimidyl 3-(2-pyridyldithio)-
propionate, Pierce Biotechnology, Inc.) and reacted with VivoT-
ag680 (Visen Medical, Inc.). The particles were ﬁltered using a
G50 (GE Healthcare) sephadex column. Next, Cystamine core,
PAMAM dendrimers were reduced using 0.5 M DTT (dithiothrei-
tol) by reacting at room temperature for 2 h. Excess DTT was re-
moved using G25 column and reduced PAMAM dendrons were
mixed with the SPDP-activated magnetic particles and allowed
to react overnight at room temperature with gentle shaking. Re-
sulting particles were separated from free dendrons by ﬁltering
several times using 100 000 molecular weight cutoff ﬁlter (Ami-
con Ultra, Millipore, Corp.), magnetic separation column (MACS,
Miltenyi Biotech) and G50 chromatography columns.
Particle Characterization. Concentration of nanoparticles was
measured as iron core concentration by measuring absorbance
at 400 nm. VivoTag concentration was measured using absor-
bance at 670 nm, and Dendron concentration was estimated by
using ninhydrin reagent and ﬂuorescamine assays. Naoparticle
charge and size was measured using zeta-potential and dynamic
light scattering instrument (Zetasizer-Nano, Malvern, Inc.). siRNA-
nanoparticle binding was characterized via electrophoresis of
the nanoparticle-siRNA (10 min incubation at room tempera-
ture) mixture on a 15% TBE gel (BioRad Laboratories) and stain-
ing siRNAs with SYBR Gold (Invitrogen, Inc.). The gel was visual-
ized using UV illumination and a SYBR green ﬁlter. For studying
the stability of the siRNAdendriworm nanoparticle, we com-
plexed the siRNA with the dendriworms for 10 min and added
ACSF to the nanoparticle solution. ACSF was prepared by mak-
ing an aqueous solution of 30 mM NaCl, 0.3 mM CaCl2, 0.5 mM
MgCl2, 0.3 mM Na2HPO4, 5.2 mM NaHCO3, and the pH was ad-
justed to 7.44. The siRNAdendriworm nanoparticles were incu-
bated in ACSF at 37 °C for the speciﬁed times and 1% SDS was
added to release the bound siRNA. The samples were analyzed
for residual siRNA by electrophoresis on a 15% TBE gel using a
similar procedure as described above.
Endosome Escape Assay. Membrane impermeable dye Calcein
(0.25 mM) or FITC-conjugated dextran (10 000 MW) were code-
livered with the various nanoparticle formulations. After 1 h, ex-
cess dye was washed off, and cells were visualized with a ﬂuores-
cence imaging system. Ratio of number of cells with endosome
escape (indicated by a diffuse cytoplasmic ﬂuorescence) and to-
tal number of cells counted from the phase contrast image was
plotted to quantify the results.
Toxicity Assessment. MTT and Calcein AM assays were per-
formed using HeLa cells in 96-well plates. Nanoparticle formula-
tions at various concentrations were incubated with the cells for
4 or 24 h. Cells were then washed three times and the reagents
were added. For MTT assay, the absorbance was read at 570 nm
after 4 h. For Calcein AM assay, cells were incubated with Cal-
cein AM for 30 min and a ﬂuorimeter was used with 485 nm ex-
citation and ﬂuorescence was read at 530 nm. Data were ana-
lyzed using Graph Pad Prism 3.03.
Convection Mediated Delivery of Nanoformulations. All of the mice
used in this study were maintained and handled under proto-
cols approved by the Committee on Animal Care at the Massa-
chusetts Institute of Technology and IACUC at Tufts University.
Osmotic minipumps (Alzet mini-osmotic pump, model 2007, Du-
rect Corp., Cupertino, CA) that maintain a constant ﬂow over 3
or 7 days at 0.5 L/h were implanted 20 days post tumor induc-
tion. The pump reservoir was ﬁlled with the dendriworms at 0.5
mg/mL. The reservoirs were connected to an intracranial cannula
(Plastics One, Roanoke, VA) through a catheter (Durect Corp., Cu-
pertino, CA) and implanted subcutaneously posterior to the site
of tumor cell implantation, until it rested on the back of the mice.
After 3 days or 7 days, the animals were sacriﬁced and brains
were processed as described above.
Histological Analysis of Tumors, Immunoﬂuorescence, and Anti-
bodies. The brains were excised and prepared for histopatholog-
ical analysis as follows: animals were deeply anesthetized with
Nembutol and transcardially perfused with PBS followed by
freshly made 4% paraformaldehyde in 0.1 M phosphate buffer,
pH 7.4. The brains were excised and postﬁxed in the same ﬁxa-
tive at 4 °C for 1 h, rinsed in PBS, and serial coronal sections were
cut using a brain mold. Tissues embedded in parafﬁn and sec-
tioned were stained with hematoxylin and eosin. For immunof-
luorescence, brains were excised and prepared for cryostat-
frozen sectioning. Sections 1012 um thick were then processed
for indirect immunoﬂuorescence against the EGF receptor us-
ing a rabbit polyclonal antibody (anti EGFR #2232, Cell Signal-
ing Technology) followed by a FITC-conjugated secondary goat
antirabbit antibody.
ImageProcessingforQuantiﬁcationofEGFRExpressionandNanoparticle
Uptake. Images of histological sections were acquired using ei-
ther a 100 magniﬁcation oil objective or a 20 magniﬁcation
objective on an inverted epiﬂuorescence microscope (Nikon In-
struments, Melville, NY) ﬁtted with a mercury arc lamp. Standard
FITC and DAPI ﬁlter cubes were used for FITC-antibody and DAPI
nuclear stains. For VivoTag680 labeled nanoparticles, Texas Red
ﬁlter cube was used. Images were collected using Coolsnap ES
camera (Roper Scientiﬁc Instruments, Acton, MA) and Meta-
morph software at 2  2 binning with ﬁxed exposure time for
each color, across all samples. Background for each image was
determined using intensity histogram and subtracted using Im-
age J (National Institutes of Health). Images were then pseudo-
colored and combined to produce composites that are shown in
Figures 4, and 5 and in the supplementary ﬁgures. Number of
green, red, or blue pixels in each image set was used to quan-
tify EGFR expression or nanoparticle uptake with respect to num-
ber of cells (blue pixels). Data from at least ﬁve RGB image sets
were pooled to produce graph, standard deviation, and p-values.
Since we are looking at reduction in EGFR expression, one tailed
p-values were calculated. This was done by using using TTEST(ar-
ray1, array2, 1,3) function in Microsoft Excel which does not as-
sume distributions with equal variance. Data were plotted using
Graph Pad Prizm software.
Gene Knockdown Assessment (Flow Cytometry, Western Blot, and
qRT-PCR). For gene silencing experiments, siRNA delivery formula-
tions were incubated with the cells for4hi nserum free me-
dium. Then, 10% serum containing medium was used to replace
the serum-free medium. Lipofectamine 2000 was used as per
supplier protocols (Invitrogen, Inc.), at concentrations shown in
the ﬁgures (e.g., 100 or 200 nM). All experiments were performed
in 96-well plates with 6000 cells at the time of starting experi-
ment in 150 L of ﬁnal volume including cell culture medium
and other reagents. For GFP knockdown assessment, (GFP siRNA
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were left in the cell culture incubator for 48 h; for EGFR knock-
down assessment, cells were incubated for 72 h. After the incu-
bation period, cells were trypsinized and resuspended in cold 1
PBS containing 1% fetal bovine serum. Reduction in GFP expres-
sion was measured using ﬂow cytometry; EGFR protein and
mRNA levels were measured using Western blot and quantita-
tive RT-PCR (Bio-Rad iCycler). Primary antibodies for Western
blots were purchased from Cell Signaling (EGF receptor anti-
body: catalog no. 2232 and GAPDH antibody: catalog no. 2118).
Western blots were developed using HRP-secondary antibody
along with the SuperSignal West Pico substrate (Pierce Biotech-
nology, Inc.). Primers for EGFR and GAPDH mRNA ampliﬁcation
and quantiﬁcation via qRT-PCR were obtained from Integrated
DNA Technologies: (EGFR forward primer) TAGAAATCATACGCG-
GCAGGACCA, (reverse primer) TCAGGCTGACGACTGCAA-
GAGAAA; (GAPDH forward primer) TCGACAGTCAGCCGCATCT-
TCTT, (reverse primer) ACCAAATCCGTTGACTCCGACCTT.
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